Is high-dose stereotactic body radiotherapy (SBRT) for stage i non-small cell lung cancer (NSCLC) overkill? A systematic review

Radiotherapy and Oncology

Volumn 105, Issue 2, 2012, Pages 145-149

  Van Baardwijk, Angela ^a   Tomé, Wolfgang A ^b   Van Elmpt, Wouter ^a   Bentzen, Soren M ^b   Reymen, Bart ^a   Wanders, Rinus ^a   Houben, Ruud ^a   Öllers, Michel ^a   Lambin, Philippe ^a   De Ruysscher, Dirk ^a,c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Lung cancer; Modelling; SABR; SBRT; Stage I; Stereotactic body radiation

Indexed keywords

CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; FOLLOW UP; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 84871336875     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2012.09.008     Document Type: Article

References (51)

1. W.J. Scott, J. Howington, and S. Feigenberg Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition) Chest 132 2007 234S 242S
2. S. Siva, M. MacManus, and D. Ball Stereotactic radiotherapy for pulmonary oligometastases: a systematic review J Thorac Oncol 5 2010 1091 1099
3. D. Palma, O. Visser, and F.J. Lagerwaard Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery Radiother Oncol 101 2011 240 244
4. A.V. Louie, G. Rodrigues, and M. Hannouf Withholding stereotactic radiotherapy in elderly patients with stage I non-small cell lung cancer and co-existing COPD is not justified: outcomes of a Markov model analysis Radiother Oncol 99 2011 161 165
5. N. Andratschke, F. Zimmermann, and E. Boehm Stereotactic radiotherapy of histologically proven inoperable stage I non-small cell lung cancer: patterns of failure Radiother Oncol 101 2011 245 249
6. N. Mohammed, I.S. Grills, and C.Y. Wong Radiographic and metabolic response rates following image-guided stereotactic radiotherapy for lung tumors Radiother Oncol 99 2011 18 22
7. R. Timmerman, R. Paulus, and J. Galvin Stereotactic body radiation therapy for inoperable early stage lung cancer JAMA 303 2010 1070 1076
8. S. Senan, D.A. Palma, and F.J. Lagerwaard Stereotactic ablative radiotherapy for stage I NSCLC: recent advances and controversies J Thorac Dis 3 2011 189 196
9. R. Timmerman, R. McGarry, and C. Yiannoutsos Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer J Clin Oncol 24 2006 4833 4839
10. N.P. Rowell, and C.J. Williams Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable) Cochrane Database Syst Rev 2001 CD002935
11. X. Qiao, O. Tullgren, and I. Lax The role of radiotherapy in treatment of stage I non-small cell lung cancer Lung Cancer 41 2003 1 11
12. J.A. Bogart, L. Hodgson, and S.L. Seagren Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904 J Clin Oncol 28 2010 202 206
13. A. van Baardwijk, S. Wanders, and L. Boersma Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer J Clin Oncol 28 2010 1380 1386
14. M.K. Martel, R.K. Ten Haken, and M.B. Hazuka Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients Lung Cancer 24 1999 31 37
15. A. van Baardwijk, G. Bosmans, and S.M. Bentzen Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trial Int J Radiat Oncol Biol Phys 71 2008 1103 1110
16. D. De Ruysscher, R. Wanders, and E. van Haren HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer Int J Radiat Oncol Biol Phys 71 2008 132 138
17. M. Saunders, S. Dische, and A. Barrett Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering Committee Radiother Oncol 52 1999 137 148
18. P. Jenkins, S. Anderson, and S. Wronski A phase II trial of induction chemotherapy followed by continuous hyperfractionated accelerated radiotherapy in locally advanced non-small-cell lung cancer Radiother Oncol 93 2009 396 401
19. A.L. Hoffmann, E.G. Troost, and H. Huizenga Individualized dose prescription for hypofractionation in advanced non-small-cell lung cancer radiotherapy: an in silico trial Int J Radiat Oncol Biol Phys 83 2012 1596 1602
20. F.J. Lagerwaard, C.J. Haasbeek, and E.F. Smit Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer Int J Radiat Oncol Biol Phys 70 2008 685 692
21. S. Bral, T. Gevaert, and N. Linthout Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a phase II trial Int J Radiat Oncol Biol Phys 80 2011 1343 1349
22. C.W. Hodge, W.A. Tome, and T. Weigel Initial clinical experience with stereotactic lung radiotherapy, based on a biological model-driven prescription method J Radiosurg SBRT 1 2011 221 229
23. C.J. Haasbeek, F.J. Lagerwaard, and B.J. Slotman Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer J Thorac Oncol 6 2011 2036 2043
24. J.J. Nuyttens, N.C. van der Voort van Zyp, and J. Praag Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors Radiother Oncol 102 2012 383 387
25. N.B. Arvidson, M.P. Mehta, and W.A. Tome Dose coverage beyond the gross tumor volume for various stereotactic body radiotherapy planning techniques reporting similar control rates for stage I non-small-cell lung cancer Int J Radiat Oncol Biol Phys 72 2008 1597 1603
26. A.M. Morgan, T. Knoos, and S.G. McNee Clinical implications of the implementation of advanced treatment planning algorithms for thoracic treatments Radiother Oncol 86 2008 48 54
27. J.F. Fowler, W.A. Tome, and J.D. Fenwick A challenge to traditional radiation oncology Int J Radiat Oncol Biol Phys 60 2004 1241 1256
28. J.P. Kirkpatrick, J.J. Meyer, and L.B. Marks The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery Semin Radiat Oncol 18 2008 240 243
29. P. Baumann, J. Nyman, and M. Hoyer Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy J Clin Oncol 27 2009 3290 3296
30. P. Baumann, J. Nyman, and I. Lax Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries Acta Oncol 45 2006 787 795
31. Y. Chen, W. Guo, and Y. Lu Dose-individualized stereotactic body radiotherapy for T1-3N0 non-small cell lung cancer: long-term results and efficacy of adjuvant chemotherapy Radiother Oncol 88 2008 351 358
32. N. Kopek, M. Paludan, and J. Petersen Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer Radiother Oncol 93 2009 402 407
33. M. Koto, Y. Takai, and Y. Ogawa A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer Radiother Oncol 85 2007 429 434
34. Y. Matsuo, K. Shibuya, and Y. Nagata Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer Int J Radiat Oncol Biol Phys 79 2011 1104 1111
35. Y. Nagata, M. Hiraoka, and T. Shibata A phase II trial of stereotactic body radiation therapy for operable T1N0M0 non-small cell lung cancer. Japan Clinical Oncology Group (JCOG0403) Int J Radiat Oncol Biol Phys 78 2010 S27 S28
36. Y. Nagata, K. Takayama, and Y. Matsuo Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame Int J Radiat Oncol Biol Phys 63 2005 1427 1431
37. J. Nyman, K.A. Johansson, and U. Hulten Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer-mature results for medically inoperable patients Lung Cancer 51 2006 97 103
38. H. Onishi, H. Shirato, and Y. Nagata Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study J Thorac Oncol 2 2007 S94 S100
39. U. Ricardi, A.R. Filippi, and A. Guarneri Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial Lung Cancer 68 2010 72 77
40. O.M. Salazar, T.S. Sandhu, and P.B. Lattin Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers Int J Radiat Oncol Biol Phys 72 2008 707 715
41. A. Takeda, N. Sanuki, and E. Kunieda Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm Int J Radiat Oncol Biol Phys 73 2009 442 448
42. G.M. Videtic, K. Stephans, and C. Reddy Intensity-modulated radiotherapy-based stereotactic body radiotherapy for medically inoperable early-stage lung cancer: excellent local control Int J Radiat Oncol Biol Phys 77 2010 344 349
43. T.B. Lanni Jr., I.S. Grills, and L.L. Kestin Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer Am J Clin Oncol 34 2011 494 498
44. J. Widder, D. Postmus, and J.F. Ubbels Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer Int J Radiat Oncol Biol Phys 81 2011 e291 e297
45. ICRU. International Commission on Radiation Units and Measurements Report 50: prescribing, recording, and reporting photon beam therapy; 1993.
46. H.J. Aerts, A.A. van Baardwijk, and S.F. Petit Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan Radiother Oncol 91 2009 386 392
47. W. van Elmpt, D. De Ruysscher, and A. van der Salm The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer Radiother Oncol 104 2012 67 71
48. D. De Ruysscher, C. Faivre-Finn, and U. Nestle European Organisation for Research and Treatment of cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer J Clin Oncol 28 2010 5301 5310
49. L.B. Marks, S.M. Bentzen, and J.O. Deasy Radiation dose-volume effects in the lung Int J Radiat Oncol Biol Phys 76 2010 S70 S76
50. M.M. Miften, A.W. Beavis, and L.B. Marks Influence of dose calculation model on treatment plan evaluation in conformal radiotherapy: a three-case study Med Dosim 27 2002 51 57
51. K.R. Muralidhar, N.P. Murthy, and A.K. Raju Comparative study of convolution, superposition, and fast superposition algorithms in conventional radiotherapy, three-dimensional conformal radiotherapy, and intensity modulated radiotherapy techniques for various sites, done on CMS XIO planning system J Med Phys 34 2009 12 22